Hiring Brief Vetted roles across BioPharma and Biotech commercial, medical affairs, and clinical functions. The recruiter's read on what each one actually signals.
Every week, this Brief puts the recruiter's read on roles that are actually worth your time. Verified companies, current listings, and one line of intelligence on what each role actually signals. Because a job title and a location do not tell you whether this is a company worth your next move.
Most companies post multiple roles. If you see a company that looks right but not the exact title you are looking for, go directly to their careers page.
All links open to company careers pages directly. Roles verified at time of publication against current layoff trackers and M&A activity. If a listing has closed, the company is still building in that function. Go straight to their careers page. Applying does not guarantee an offer.
Week of April 24, 202
Core Commercial Builds
These companies are where the heaviest commercial buildouts are happening right now: field leadership, market access, medical affairs, and pre-launch commercialization, not just isolated backfills. If you were hit by a CRL, a restructuring, or a “strategic realignment” this quarter, this is where to look next.
Compass Pathways · Mental Health (TRD, PTSD) · Pre-Launch
Careers:Compass Pathways Careers
Multiple US roles open
Why now: Furthest-advanced psilocybin program in history: two consecutive positive Phase 3 trials in treatment‑resistant depression, Breakthrough Therapy designation, and a rolling NDA targeting Q4 2026. The April 18 psychedelics executive order is a direct regulatory tailwind. You would be helping build the first psychedelic commercial infrastructure the FDA has ever seen — supervised clinic model, REMS, payer strategy, all from the ground up.
BridgeBio Pharma · Rare Genetic Disease (ATTR‑CM, LGMD2I, ADH1, achondroplasia) · Launch + Pre‑Launch
Careers:BridgeBio Careers
Multiple US roles open
Why now: Attruby (acoramidis) for ATTR‑CM is already approved and commercial, with two more NDAs planned for H1 2026 (LGMD2I and ADH1), putting BridgeBio into multi‑launch mode. Named #1 Best Place to Work by BioSpace in 2026 for small biotechs, they combine real revenue, upcoming NDAs, and scale‑up hiring across every commercial function.
Revolution Medicines · Precision Oncology (RAS‑addicted cancers) · Pre‑Launch
Careers:Revolution Medicines Careers
Multiple US roles open
Why now: One of the hottest precision oncology companies attacking the RAS oncogene family (KRAS G12C, KRAS G12D, pan‑RAS) that drives roughly 30% of human cancers. Backed by about $750M in funding, they’re hiring commercial strategy, access, and medical roles before any PDUFA date — classic ground‑floor oncology build rather than late‑cycle “bolt‑on” roles.
Corcept Therapeutics · Oncology (Platinum‑Resistant Ovarian Cancer) & Endocrinology (Cushing’s) · Approved + Launch
Careers:Corcept Therapeutics Careers
Multiple US roles open
Why now: Lifyorli (relacorilant) was FDA‑approved on March 25, 2026 for platinum‑resistant ovarian cancer; Korlym is a long‑commercialized Cushing’s therapy. That means active launch mode for a new oncology indication funded by an existing profitable franchise — a rare combination of launch upside and financial stability.
Summit Therapeutics · Oncology (EGFR‑mutated NSCLC) · Pre‑Launch
Careers:Summit Current Openings
Multiple US roles open
Why now: Ivonescimab, their PD‑1/VEGF bispecific, has a PDUFA date of November 14, 2026 for EGFR‑mutated NSCLC post‑TKI. Summit is building the entire commercial infrastructure now market access, sales ops, medical affairs, with field sales expected to follow closer to PDUFA. This is one of the highest‑urgency oncology pre‑launch builds on the calendar.
Pharvaris · Rare Disease (HAE) · Pre‑NDA
Careers:Pharvaris Careers
Multiple US roles open
Why now: Entire US commercial organization being built from scratch ahead of the first‑ever oral HAE therapy (deucrictibant), with NDA filing targeted for H1 2026 and prophylactic CHAPTER‑3 data expected Q3 2026. This is a classic rare‑disease ground‑floor build in a competitive market (Takeda, BioCryst, KalVista) where the early team will decide whether they carve share or fade.
Krystal Biotech · Gene Therapy (DEB) · Approved + Expanding
Careers:Krystal Biotech Careers
Multiple US roles open
Why now: Vyjuvek, their gene therapy for dystrophic epidermolysis bullosa (DEB), is commercial and profitable — over $730M cumulative US net revenue and an expanded label in 2026 (patients from birth, at‑home administration). This is true expansion hiring because the launch is working, not mid‑launch firefighting.
IDEAYA Biosciences · Metastatic Uveal Melanoma
Careers: IDEAYA Careers
Multiple US roles open
Why now: Positive Phase 2/3 registrational data for darovasertib + crizotinib in first‑line metastatic uveal melanoma, with a late‑breaking oral at ASCO 2026 locked and commercialization planning now a 2026 corporate objective. Early commercial, HEOR/RWE, and medical affairs roles around this first‑in‑class launch are beginning to surface.
Plus additional roles in: Clinical development, translational oncology, and program leadership that will sit close to the launch.
Denali Therapeutics · Hunter Syndrome (CNS)
Careers: Denali Careers
Why Now: Avlayah (tividenofusp alfa) just received accelerated approval for neurologic manifestations of Hunter syndrome, using Denali’s BBB‑shuttle platform and carrying breakthrough, fast track, priority review, and orphan designations. Denali is now shifting from a pure R&D shop into a rare‑disease commercial company and standing up focused launch capabilities around Avlayah.
Plus additional roles in: Field medical, market access, and patient services tied to Avlayah, along with development roles on next‑wave BBB programs.
Immunome · Oncology (Desmoid Tumors) · Pre‑NDA
Careers:Immunome Careers
Multiple US roles open
Why now: Phase 3 RINGSIDE trial of varegacestat showed an 84% reduction in disease progression in desmoid tumors; NDA submission is planned for Q2 2026, with PDUFA likely Q4 2026–Q1 2027. They are actively building full commercial infrastructure now — rare chance to help define an ultra‑rare oncology market from the ground up.
Before you apply, know exactly where you stand. 60 minutes with Yaffa. A clear read on your positioning and what needs to change before you send anything.
Additional Companies
Viridian Therapeutics · Thyroid Eye Disease (TED)
Veligrotug BLA accepted with Priority Review; PDUFA June 30, 2026. Hiring across field sales, sales analytics, patient access, and commercial ops ahead of launch.
Careers: Viridian Careers
Capricor Therapeutics · DMD Cardiomyopathy
Deramiocel BLA re‑accepted; PDUFA August 22, 2026 for the first cell therapy in DMD cardiomyopathy. Senior Director Medical Affairs (MD) and other pre‑commercial roles are open.
Plus additional roles in: Clinical operations, manufacturing, and program management around the cell‑therapy platform.
Careers: Capricor Careers
Protagonist Therapeutics / Takeda · Polycythemia Vera (PV)
Rusfertide NDA accepted; PDUFA Q3 2026. Takeda partnership with co‑promotion rights in the US.
Plus additional roles in: Clinical, regulatory, and program strategy that will interface with co‑promotion.
Careers: Protagonist Careers
Orca Bio · Precision Cell Therapy (AML/ALL/MDS)
Orca‑T BLA accepted with PDUFA July 6, 2026. Small, high‑science team preparing to build full commercial infrastructure for curative‑intent cell therapy.
Plus additional roles in: Manufacturing, clinical operations, and quality to support launch‑scale production.
Careers: Orca Bio Careers
PharmaEssentia · Rare Hematology (PV, ET)
BESREMi is commercial in PV; sBLA PDUFA August 30, 2026 for essential thrombocythemia. US field expansion is underway.
Plus additional roles in: MSLs, medical, and operations as the franchise broadens.
Careers: PharmaEssentia Careers
Alnylam Pharmaceuticals · RNAi Rare Disease Platform
Multiple commercial products in ATTR, AHP, and beyond with ongoing TTR and cardiology field expansion.
Plus additional roles in: Medical affairs, HEOR, and commercial ops supporting the broader RNAi portfolio.
Careers: Alnylam Careers
Ionis Pharmaceuticals · Antisense Platform (Neuro, CV, Rare Metabolic)
Deep late‑stage antisense pipeline; tends to hire ahead of key data readouts in clinical‑adjacent and commercial planning roles.
Plus additional roles in: Program leadership, clinical development, and allied commercial functions.
Careers: Ionis Careers
Nuvation Bio · Myelofibrosis / Prostate (MDM2 inhibitor)
Navtemadlin’s Phase 3 readout is approaching; early commercial and medical planning roles are starting to surface.
Plus additional roles in: Clinical operations, translational science, and corporate functions as they prepare for potential NDA.
Careers: Nuvation Careers
Insmed · Non‑CF Bronchiectasis
Brinsupri (brensocatib) was approved in 2025 as the first and only treatment for non‑CF bronchiectasis after FDA granted priority review, and Insmed is now in year‑two launch expansion scaling pulmonology access, adding commercial analytics, and deepening field presence.
Plus additional roles in: Medical affairs, global marketing, and clinical development that support Brinsupri and the broader pipeline.
Careers: Insmed Careers
Not seeing your function? Tell me what you are looking for. I read every one.
Tell me what you need →Make sure you are worth calling back. 60 minutes. $250. Know exactly where you stand before you apply to anything. Book a Strategy Session →